Home » Topics » BioWorld Science

BioWorld Science
RSS

Lycera updates on ROR-gamma agonists LYC-54143 and LYC-55716

May 3, 2018

Patient enrollment ongoing in phase I study of CSJ-117 in atopic asthma

May 3, 2018

MOR-106 moves into phase II development for atopic dermatitis with IGUANA trial

May 3, 2018

NeoImmuneTech enters clinical trial collaboration with Roche

May 3, 2018

FDA grants rare pediatric disease designation to CLR-131 for neuroblastoma

May 3, 2018

Millennium Pharmaceuticals initiates first-in-human trial of TAK-164

May 3, 2018

First-in-human study of hepatitis B DNA vaccine JNJ-64300535

May 3, 2018

Enrollment ongoing in phase III trial of enfortumab vedotin for urothelial cancer

May 3, 2018

EMA approves Alpivab for the treatment of influenza

May 3, 2018

YW-1128, a WNT pathway inhibitor, shows promising in vivo results for metabolic disorders

May 3, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...